Last summer, deep disappointment befell the Alzheimer disease (AD) community when study results showed that the widely heralded experimental drug LMTX had failed to help AD patients. In November, another promising drug, solanezumab, also dashed hopes. Because these drugs target either amyloid β (solanezumab) or tau (LMTX), proteins that aggregate into the plaques and tangles in brain tissue characteristic of AD, some have suggested that researchers are following the wrong path by attacking these proteins and that AD research is back to square one after decades of work.
Lyon J. Alzheimer Outlook Far From Bleak. JAMA. 2017;317(9):896-898. doi:10.1001/jama.2017.0276